[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 154
Citations 0
From JAMA's Daily News Site
September 4, 2013

From JAMA’s Daily News Site

JAMA. 2013;310(9):893. doi:10.1001/jama.2013.276468

As countries begin using a new drug to treat multidrug-resistant tuberculosis (MDR-TB), authorities urge caution to prevent drug resistance from emerging and to protect patients from potential adverse effects.

Bedaquiline is the first TB drug with a novel mechanism to be approved in 40 years. However, the World Health Organization (WHO) cautioned that the drug has not yet completed the final phase of clinical testing. The US Food and Drug Administration fast-tracked bedaquiline’s approval through its orphan drug program. In an unprecedented step, the WHO issued an interim guidance on using the drug.